Sanofi (SNY)
(Delayed Data from NSDQ)
$46.75 USD
+1.11 (2.43%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $46.00 -0.75 (-1.60%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SNY 46.75 +1.11(2.43%)
Will SNY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNY
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
SNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
Other News for SNY
Notable healthcare headlines for the week: Trump’s ultimatum to big pharma, Novo Nordisk, UnitedHealth and Moderna in focus
Top global stories this week: HSBC, AstraZeneca, Nissan among notable names
Market Voices: Trump vs. Big Pharma, Swiss tariffs, tariff legality
Putnam U.S. Large Cap Value Equity Concentrated SMA Q2 2025 Commentary
Experts helping vaccine advisors are reportedly ousted at CDC